Development of an immunochromatographic lateral flow assay to rapidly detect OXA-23-, OXA-40-, OXA-58- and NDM-mediated carbapenem resistance determinants in Acinetobacter baumannii
Journal of Medical Microbiology · 12.04.2023 · 72 (4)
DOI: 10.1099/jmm.0.001681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology, erschienen am 12.04.2023. Verfasst von Sonja Mertins und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germ…. Hauptthemen laut MEDLINE: Acinetobacter baumannii. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Zentrum für Infektionsforschung, Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, European Regional Development Fund.
Abstract (Originalsprache)
Introduction
Acinetobacter baumannii infections can be extremely challenging to treat owing to the worldwide prevalence of multidrug-resistant isolates, especially against carbapenems. Colonization with carbapenem-resistant A. baumannii (CRAb) requires rapid action from an infection control perspective because the organism is known for its propensity for epidemic spread . Hypothesis/Gap Statement. There is an unmet medical need to rapidly identify CRAb to enable appropriate antimicrobial treatment and to prevent transmission .
Aim
Our aim was to expand the OXA-detection abilities of the rapid immunochromatographic test (ICT) OXA-23 K -SeT (Coris BioConcept) to include OXA-40- and OXA-58-like carbapenemases, which together confer carbapenem resistance to more than 94 % of CRAb isolates worldwide . Methodology. We used hybridoma technology to generate mAbs against OXA-40 and OXA-58 and selected them for productivity and specificity against recombinant and endogenous OXA-40 and OXA-58. Combinations of the resulting mAbs were analysed in ICT format for their ability to detect recombinant rOXA-40 His6 or rOXA-58 His6 , respectively. Subsequently, selected antibody pairs were implemented into single-OXA-40 or single-OXA-58 prototypes and the final OXA-23/40/58/NDM ICT and were evaluated on clinical Acinetobacter spp. isolates with well-defined carbapenem resistance mechanisms .
Results
Five anti-OXA-40 and anti-OXA-58 mAbs were selected. Competition ELISA with combinations of these antibodies revealed that the anti-OXA-40 antibodies bind to one of two binding clusters on OXA-40, while anti-OXA-58 antibodies bind to one of four binding clusters on OXA-58. Direct binding to the corresponding antigen in an ICT format has left only three antibodies against rOXA-40 His6 and rOXA-58 His6 , respectively for the subsequent sandwich ICT selection procedure, which revealed that the anti-OXA-40 (#5) and anti-OXA-58 (#A8) mAbs in combination with the cross-reactive mAb #C8 performed best. They were implemented into single-OXA-40 and single-OXA-58 ICT prototypes and evaluated. These single ICT prototypes demonstrated 100 % specificity and sensitivity. Based on these results, an OXA-23/40/58/NDM-ICT was developed, complemented with OXA-23 and NDM-specific detection. An evaluation with selected carbapenem-resistant Acinetobacter spp. isolates ( n =34) showed 100 % specificity .
Conclusion
With this easy-to-use detection assay, one can save 12–48 h in diagnostics, which helps to treat patients earlier with appropriate antibiotics and allows immediate intervention to control transmission of CRAb .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- German Center for Infection Research (DZIF), Partner site Bonn-Cologne, Cologne, Germany.
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
- Coris BioConcept, Science Park CREALYS, Rue Jean Sonet 4A, B-5032 Gembloux, Belgium.
Förderung
- Deutsches Zentrum für Infektionsforschung
- Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen
- European Regional Development Fund
Zitieren
APA
Mertins, S., Higgins, P. G., Thunissen, C., Magein, H., Gilleman, Q., Mertens, P., Rodríguez, M. G., Maus, L. M., Seifert, H., Krönke, M., & Klimka, A. (2023). Development of an immunochromatographic lateral flow assay to rapidly detect OXA-23-, OXA-40-, OXA-58- and NDM-mediated carbapenem resistance determinants in Acinetobacter baumannii. Journal of Medical Microbiology, 72(4). https://doi.org/10.1099/jmm.0.001681
Vancouver
Mertins S, Higgins PG, Thunissen C, Magein H, Gilleman Q, Mertens P, et al. Development of an immunochromatographic lateral flow assay to rapidly detect OXA-23-, OXA-40-, OXA-58- and NDM-mediated carbapenem resistance determinants in Acinetobacter baumannii. Journal of Medical Microbiology. 2023;72(4). doi:10.1099/jmm.0.001681
BibTeX
@article{Mertins2023,
author = {Mertins, Sonja and Higgins, Paul G and Thunissen, Caroline and Magein, Henri and Gilleman, Quentin and Mertens, Pascal and Rodríguez, María González and Maus, Liza Marie and Seifert, Harald and Krönke, Martin and Klimka, Alexander},
title = {Development of an immunochromatographic lateral flow assay to rapidly detect OXA-23-, OXA-40-, OXA-58- and NDM-mediated carbapenem resistance determinants in Acinetobacter baumannii},
journal = {Journal of Medical Microbiology},
year = {2023},
volume = {72},
number = {4},
doi = {10.1099/jmm.0.001681}
}
EUVIMED